Aliyu S H, Enoch D A, Abubakar I I, Ali R, Carmichael A J, Farrington M, Lever A M L
Infectious Diseases Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge CB2 2QQ.
QJM. 2006 Oct;99(10):655-63. doi: 10.1093/qjmed/hcl087. Epub 2006 Aug 25.
Candidaemias are associated with significant morbidity and mortality. The British Society of Medical Mycology and Infectious Diseases Society of America recently published audit standards, to address the changing epidemiology of candidaemia and to improve outcomes.
To investigate the local epidemiology of candidaemia and the standard of care in a large teaching hospital.
Retrospective audit.
Data were obtained for all candidaemia episodes over the 4-year period ending July 2004, from the medical and nursing notes, laboratory computer and patient administration system.
We identified 92 episodes in 90 patients. The main predisposing factors were being on an intensive care unit, having a central venous catheter, and (for neonates) prematurity. Central venous catheters were removed at a mean 1.8 days following candidaemia; 79% (37/47) were removed within 48 h (the audit standard). Identification and susceptibility tests were performed for 94.7% of isolates. All were susceptible to amphotericin B; 87% were susceptible to fluconazole. Antifungal treatment was started within 24 h of a positive blood culture in 84% of episodes. Initial antifungal therapy was appropriate in 95% (61/64) of treated cases. Most patients (81%) who survived or completed their intended course of treatment before death received at least 2 weeks treatment. However, only 45% of those transferred to other hospitals had accompanying guidance on the intended further duration of therapy. Thirty-day mortality was 41%. After adjustment for age, the presence of Candida-related complications was associated with an odds ratio for mortality of 6.5 (95% CI 1.2-36.5, p = 0.03).
Overall the audit standards set by the BSMM and IDSA were met, and discrepancies did not lead to a change in outcome. Improved intravenous catheter care, a more pro-active approach to searching for complications, and improvement in the inter-hospital transfer process, will assist in reducing morbidity and mortality.
念珠菌血症与显著的发病率和死亡率相关。英国医学真菌学会和美国传染病学会最近发布了审核标准,以应对念珠菌血症不断变化的流行病学情况并改善治疗结果。
调查一家大型教学医院中念珠菌血症的当地流行病学情况及护理标准。
回顾性审核。
从医疗和护理记录、实验室计算机系统及患者管理系统中获取了截至2004年7月的4年期间内所有念珠菌血症发作的数据。
我们在90名患者中识别出92次发作。主要的易感因素是入住重症监护病房、有中心静脉导管以及(对于新生儿)早产。念珠菌血症发作后,中心静脉导管平均在1.8天被拔除;79%(37/47)在48小时内被拔除(审核标准)。94.7%的分离株进行了鉴定和药敏试验。所有分离株对两性霉素B敏感;87%对氟康唑敏感。84%的发作在血培养阳性后24小时内开始抗真菌治疗。95%(61/64)的治疗病例初始抗真菌治疗是恰当的。大多数存活或在死亡前完成预定疗程的患者(81%)接受了至少2周的治疗。然而,转至其他医院的患者中只有45%收到了关于预定进一步治疗疗程的指导。30天死亡率为41%。在对年龄进行调整后,念珠菌相关并发症的存在与死亡比值比为6.5(95%可信区间1.2 - 36.5,p = 0.03)相关。
总体而言,英国医学真菌学会和美国传染病学会设定的审核标准得到了满足,差异并未导致结果改变。改善静脉导管护理、采取更积极主动的方法寻找并发症以及改进医院间转运流程,将有助于降低发病率和死亡率。